inclusion criteria: * patients who have signed a written consent to participate in the study * hospitalized patients with a diagnosis: covid-19 coronavirus disease confirmed by laboratory testing regardless of the severity of clinical signs no later than 72 hours before screening (u07.1 - virus was identified), or covid-19 coronavirus disease, when the infection is diagnosed clinically or epidemiologically no later than 72 hours before screening, but laboratory tests are inconclusive or unavailable (u07.2 - virus was not identified), moderate form. to be classified as a moderate form, the patient must have at least one of the following criteria: body temperature \> 38 °c; respiratory rate (rr) \> 22/min; shortness of breath during physical exertion; ct (radiography) findings typical of viral lesion (minimal or average lesion volume, grade 1-2 on ct); spo2\<95 %; serum c reactive protein (crp) \> 10 mg/l * males and non-pregnant females (negative pregnancy test or human chorionic gonadotropin (hcg) blood test (for females with childbearing potential)) at the age of 18 to 85 years * patients who are able to comply with all the requirements of the study protocol; * patients who agreed to use adequate methods of contraception during the entire study and for at least 7 days after the end of the study

inclusion criteria: * patients who have signed a written consent to participate in the study * hospitalized patients with a diagnosis: covid-19 coronavirus disease confirmed by laboratory testing regardless of the severity of clinical signs no later than 72 hours before screening (u07.1 - virus was identified), or covid-19 coronavirus disease, when the infection is diagnosed clinically or epidemiologically no later than 72 hours before screening, but laboratory tests are inconclusive or unavailable (u07.2 - virus was not identified), moderate form. to be classified as a moderate form, the patient must have at least one of the following criteria: body temperature \> 38 °c; respiratory rate (rr) \> 22/min; shortness of breath during physical exertion; ct (radiography) findings typical of viral lesion (minimal or average lesion volume, grade 1-2 on ct); spo2\<95 %; serum c reactive protein (crp) \> 10 mg/l * males and non-pregnant females (negative pregnancy test or human chorionic gonadotropin (hcg) blood test (for females with childbearing potential)) at the age of 18 to 85 years * patients who are able to comply with all the requirements of the study protocol; * patients who agreed to use adequate methods of contraception during the entire study and for at least 7 days after the end of the study

inclusion criteria: patients who have signed a written consent to participate in the study hospitalized patients with a diagnosis: covid-19 coronavirus disease confirmed by laboratory testing regardless of the severity of clinical signs no later than 72 hours before screening (u07.1 - virus was identified), or covid-19 coronavirus disease, when the infection is diagnosed clinically or epidemiologically no later than 72 hours before screening, but laboratory tests are inconclusive or unavailable (u07.2 - virus was not identified), moderate form. to be classified as a moderate form, the patient must have at least one of the following criteria: body temperature > 38 °c; respiratory rate (rr) > 22/min; shortness of breath during physical exertion; ct (radiography) findings typical of viral lesion (minimal or average lesion volume, grade 1-2 on ct); spo2<95 %; serum c reactive protein (crp) > 10 mg/l males and non-pregnant females (negative pregnancy test or human chorionic gonadotropin (hcg) blood test (for females with childbearing potential)) at the age of 18 to 85 years patients who are able to comply with all the requirements of the study protocol; patients who agreed to use adequate methods of contraception during the entire study and for at least 7 days after the end of the study

inclusion criteria: patients who have signed a written consent to participate in the study hospitalized patients with a diagnosis: covid-19 coronavirus disease confirmed by laboratory testing regardless of the severity of clinical signs no later than 72 hours before screening (u07.1 - virus was identified), or covid-19 coronavirus disease, when the infection is diagnosed clinically or epidemiologically no later than 72 hours before screening, but laboratory tests are inconclusive or unavailable (u07.2 - virus was not identified), moderate form. to be classified as a moderate form, the patient must have at least one of the following criteria: body temperature > 38 °c; respiratory rate (rr) > 22/min; shortness of breath during physical exertion; ct (radiography) findings typical of viral lesion (minimal or average lesion volume, grade 1-2 on ct); spo2<95 %; serum c reactive protein (crp) > 10 mg/l males and non-pregnant females (negative pregnancy test or human chorionic gonadotropin (hcg) blood test (for females with childbearing potential)) at the age of 18 to 85 years patients who are able to comply with all the requirements of the study protocol; patients who agreed to use adequate methods of contraception during the entire study and for at least 7 days after the end of the study